BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 30334460)

  • 1. Prognostic factors for multiple myeloma in the era of novel therapies.
    Ziogas DC; Dimopoulos MA; Kastritis E
    Expert Rev Hematol; 2018 Nov; 11(11):863-879. PubMed ID: 30334460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Review on High-Risk Multiple Myeloma.
    Chan HSH; Chen CI; Reece DE
    Curr Hematol Malig Rep; 2017 Apr; 12(2):96-108. PubMed ID: 28317082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in understanding prognosis in myeloma.
    Smith D; Yong K
    Br J Haematol; 2016 Nov; 175(3):367-380. PubMed ID: 27604166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigative tools for diagnosis and management.
    Munshi NC
    Hematology Am Soc Hematol Educ Program; 2008; ():298-305. PubMed ID: 19074100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Established and Novel Prognostic Biomarkers in Multiple Myeloma.
    Bustoros M; Mouhieddine TH; Detappe A; Ghobrial IM
    Am Soc Clin Oncol Educ Book; 2017; 37():548-560. PubMed ID: 28561668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRD Assessment in Multiple Myeloma: Progress and Challenges.
    Bertamini L; D'Agostino M; Gay F
    Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.
    Kazmi SM; Nusrat M; Gunaydin H; Cornelison AM; Shah N; Kebriaei P; Nieto Y; Parmar S; Popat UR; Oran B; Shah JJ; Orlowski RZ; Champlin RE; Qazilbash MH; Bashir Q
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):687-93. PubMed ID: 26361647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk stratification in multiple myeloma, part 1: characterization of high-risk disease.
    Biran N; Jagannath S; Chari A
    Clin Adv Hematol Oncol; 2013 Aug; 11(8):489-503. PubMed ID: 24518420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Critical Role of Imaging in the Management of Multiple Myeloma.
    Raza S; Leng S; Lentzsch S
    Curr Hematol Malig Rep; 2017 Jun; 12(3):168-175. PubMed ID: 28317080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of high-risk Myeloma: an evidence-based review of treatment strategies.
    Lehners N; Hayden PJ; Goldschmidt H; Raab MS
    Expert Rev Hematol; 2016 Aug; 9(8):753-65. PubMed ID: 27337562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple myeloma: is it time for biomarker-driven therapy?
    Bhutani M; Landgren O; Usmani SZ
    Am Soc Clin Oncol Educ Book; 2015; ():e493-503. PubMed ID: 25993214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple myeloma.
    White TB; Caldwell D; Hall-Rollins J
    Radiol Technol; 2005; 76(5):379-88; quiz 389-91. PubMed ID: 15921017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent Cytogenetic Abnormalities in Multiple Myeloma.
    Chan NC; Chan NP
    Methods Mol Biol; 2017; 1541():295-302. PubMed ID: 27910031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel biomarkers in multiple myeloma.
    Levin A; Hari P; Dhakal B
    Transl Res; 2018 Nov; 201():49-59. PubMed ID: 30301522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.
    Neben K; Jauch A; Bertsch U; Heiss C; Hielscher T; Seckinger A; Mors T; Müller NZ; Hillengass J; Raab MS; Ho AD; Hose D; Goldschmidt H
    Haematologica; 2010 Jul; 95(7):1150-7. PubMed ID: 20220069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-risk Multiple Myeloma: Definition and Management.
    Joseph NS; Gentili S; Kaufman JL; Lonial S; Nooka AK
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S80-S87. PubMed ID: 28760306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to Think About Risk in Myeloma.
    Krishnan A
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S135-8. PubMed ID: 27521310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Cytogenetic Analysis of Chromosome 8 Aberrations in Patients With Multiple Myeloma Examined in 2 Different Stages, at Diagnosis and at Progression/Relapse.
    Mlynarcikova M; Balcarkova J; Mickova P; Scudla V; Pika T; Bacovsky J; Minarik J; Janousova E; Jarosova M
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):358-65. PubMed ID: 27052024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Staging and prognostication of multiple myeloma.
    Fonseca R; Monge J; Dimopoulos MA
    Expert Rev Hematol; 2014 Feb; 7(1):21-31. PubMed ID: 24483346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.
    Stewart AK; Fonseca R
    J Clin Oncol; 2005 Sep; 23(26):6339-44. PubMed ID: 16155017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.